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875-5 Antiinflammatory and Antiangiogenetic Effect of 
Ramiprilat: Angiotensin Converting Enzyme Inhibition 
in Monocytes Prevents Their Angiotensin II- and 
Hypoxia-Induced Cytokine Expression by 
Downregulation of AT-1 Receptor Expression and NF- 
kappa6 Activation 
Alexander Schmeisser, Oliver Soehnlein, Thomas Illmer, Christoph Garlichs, Hannes 
Lorenz. Gerhard Ehninaer. Werner G. Danrel. Ruth H. Strasser. Technical Universitv of 
Dresden, Dresden, Germany, University Erlangen-Nuernberg, Erlangen, Germany 
Background: There are several controversal reports regarding the effects of ACE inhibi- 
tors on the plaque angrogenesis in atherosclerosis and tumor growth. An antiinflamma- 
tory and antiangiogenic effect of ACE-inhibition might be of major relevance in acute 
coronary syndromes. Because the Angrotensin II (ATII)-ATl-receptor(R)- and hypoxia- 
derived angiogenesis is induced by supporting mononuclear cell (MNC) infiltration and 
angiogenic cytokine expression we examined the effects of ACE inhibition on the stimu- 
lation of Monocytes by ATII and hypoxia. 
Methods: Human MO were stimulated rn vitro 1. with 100 and 500 nM ATII and 2. with 
hypoxia (02:3%). In 1. MO were pretreated with 1 ,B,lOmicroM ramiprilat @a), ATl-R 
Inhibitor (I) Losartan (1microM) or AT2-RI PDl23,319 (1microM) and in 2. with 
1 ,S,lOmicroM Ra. Analysis of monocytic ATIR-R expression was performed by western 
blotting, NF-kappaB by EMSA, IL-8 and MCP-1 by RT-PCR and ELISA, statistics by sto- 
dents t-test (sign: p-zO.05). In 10 samples of advanced human atherosclerotic carotid 
plaques (AHP) immunohrstochemic starning for ACE, IL-8 and MCP-1 was performed. 
Results: In 100% of inflammatory shoulder regions of AHP colocalization of MNC-ACE 
with MCP-1 and IL-8 could be demonstrated. In vitro, hypoxia stimulated MO IL-8 and 
MCP-1 expression was inhibited with Ra by 65+/-13% and 48+/-l 1% (PcO.01). respec- 
tively. MO ATII-ATl-R induced IL-8 and MCP-1 expression could also Inhibited by 49+1- 
4% and 71+/-5% with Ra rn dose-dependent manner. Ra (10microM) reduced the 
hypoxia- and ATII-induced NF-kappaB actrvation only slightly (p=O.8). But, Ra 
(IOmicroM) reduced the monocyte ATI-R expression by 50+/-12% and 83+/-13% after 
12 and 24h highly significant (pcO.001). The ATP-R expression remarned unchanged. 
Conclusion: For the first time, it could be demonstrated that antrinflammatory effects of 
ACE inhibition could be derived by a marked downregulation of monocytic AT1 -R expres- 
sion, and by an Inhibition of the hypoxra-induced proinflammatory and angiogenic MCP-1 
and IL-8 productron. These effects of Ra mrght be of major relevance in atherosclerotic 
plaque vulnerabrlity. 
9:45 a.m. 
875-8 Effect of Exercise Training in Patients With Coronary 
Artery Disease on Circulating Endothelial Progenitor 
Cells 
Karsten Lenk, Volker Adams, Marcus Sandri, Atila Tarnok, Dominik Lens, Andrej 
Schmidt, Dirk Scheinert, Dirk Schetnert. Gerhard Schuler, Rainer Hambrecht. Universrty 
of Leipzig, Heart Center, Leipzig, Germany 
In patients with coronary artery disease (CAD) exercrse training (ET) is regularly associ- 
ated with a decrease in exercise-induced myocardial ischemia. Recently it has been 
shown that a symptom-limited exercrse test is sufhcrent to increase circulating endothslral 
progenitor cells (EPC) in patients with symptomatrc CAD. Until now, however less IS 
known about the impact of regular ET on the amount of circulating EPCs. Aim of thus 
stodv was to investroate the effects of ET on the number of EPCs in oatrents with svfno- 
tomatic CAD. To define the role of ischemia during ET we also analyzed the effect‘of 
treadmill trainino in oatrents with oerioheral arterv occlusive disease iPAODI bevond the _ i ,  
ischemic threshold. 14 patients with CAD and 14 patients with PAOD were randomly 
assigned either to (ET) or an inactive control group (C). Ergometer and treadmill training 
was performed 6 times daily for a period of 4 weeks. The concentration of EPCs was 
analyzed by FACS-analysis of CD34+/KDR+ cells. In cell culture the amount of EPCs 
was determined by analyzing Di-LDL and FITC-Lectin double positive stained cells using 
Laser Scanning Cytometry. After 4 weeks of ET crrculating EPCs showed ho srgnificant 
differences in IP rn comparison to baseline levels (cell culture: 1.6+0.5fold increase ; n.s. 
vs. baseline and C ; FACS: 1.3*0.3fold increase , n.s. vs. baseline and C). In PAOD 
patients regular ET leads to a significant increase of EPC during the training period with a 
peak after 3 weeks (cell culture: 6.2+3.4fold increase ; peO.01 vs. baseline and C ; 
FACS: 3.2+1.8fold increase , p<O.Ol vs. baseline and C). In conclusion, the present 
study demonstrates that exercise training in symptomatic CAD patients below the 
ischemic threshold is Insufficient to induce an increase in the number of circulating EPCs. 
In contrast treadmill training in PAOD patients beyond the ischemfc threshold seems to 
be a potent trigger for an EPC release. 
8:30 am. 
876-1 Aggressive Treatment Aimed at Raising High-Density 
Lipoprotein Cholesterol in Stable Patients With 
Angiographically Evident Coronary Disease Prevents 
Stenosis Progression and Reduces Cardiovascular 
Events 
Richard A. Krasuski Ara M. Maranian, Edwrn J. Whitney, Bradley E. Personios, B. Greg 
Brown, Antonio M. Gotto, Jr., Wilford Hall Medical Center, San Antonio, TX 
Background: Overwhelming evidence supports that lowering low-density lipoprotein 
cholesterol (LDL-c), particularly with statins, leads to a reduction in cardiovascular 
events. High-density lipoprotein cholesterol (HDL-c). despite being a stronger predictor 
of events in epidemiologic studies, has been mostly neglected es the focus of therapy. 
Methods: We performed a randomized double-blind, placebo-controlled trial assessing 
the effect of gemfibrozil, niacin, and cholestyramrne on a baseline of aggressive dretary 
and lifestyle intervention. Patrents ~76 years of age with angiographically-evident coro- 
nary disease in the absence of recent instability were consented and followed over a 
period of 30 months. Quantitative angiography was performed at baselrne and at the 
completion of the study. 
Results: In the 143 randomized patients, mean age was 63 * 7 years and 8% were 
women. Baseline characteristics included total cholesterol 195 * 31 mgldl, LDL-c 127 * 
27 mgidl, HDL-c 34 i- 6 mg/dl, triglycehdes 169 * 82 mg/dl. systolic blood pressure 139 * 
16 mm Hg, and fashng blood sugar 80 f 14 mgldl. No difference in baseline characteris- 
tics was seen between the 2 groups. Median weight loss during the study was 1% in the 
placebo group and 4% in the drug group, p-zO.001. Total cholesterol increased by 3% in 
the placebo group but was reduced by 16% in the drug group, p<O.OOl. LDL-c increased 
by 21% in the placebo group but dropped by 5% in the drug group, p<O.OOl. HDL-c 
increased by 2% in the placebo group and by 37% in the drug group, p<O.OOl. Triglycer- 
Ides increased by 3% in the placebo group but were reduced by 45% in the drug group, 
pcO.001. Fasting blood sugar increased by 8% oh placebo group and by 18 % on drug 
therapy, p=O.O06. Focal coronary stenosis increased by 1% on placebo but decreased by 
1% in the drug group, p=O.O43. A combined endpoint of unstable angina, transient 
ischemic attack and stroke, percutaneous intervention, coronary bypass, or death was 
reached in 19 placebo patients and 9 drug patients, p=O.O39. 
Conclusion:A combination of agents aimed at increasing HDL-c dramatically knproves 
cholesterol profiles, arrests angiographic progression, and results in a significant reduc- 
tion in cardiovascular events. 
8:45 a.m. 
876-2 Statin Therapies for Elevated Lipid Levels Compared 
Across Dose Ranges to Rosuvastatin: Low-Density 
Lipoprotein Cholesterol and High-Density Lipoprotein 
Cholesterol Results 
Peter H. Jones for the STELLAR Study Group, Baylor College of Medicine, Houston, TX 
Background: The primary objective of this large, multicenter trial was to compare the 
effects of rosovastatin (RSV) versus atorvastatin (ATV), simvastatin (SIM), and pravasta- 
tin (PRA) across dose ranges on percent changes in low-density lipoprotein-cholesterol 
(LDL-C). 
Methods: After discontinuation of lipid-lowering drugs and a 6.week dietary lead-in 
period, 2431 adults with hypercholesterolemia (LDL-CY60 mg/dL and ~250 mg/dL; trig- 
lycerides ~400 mg/dL) were randomrzed to 15 parallel, open-label treatments for 6 
weeks. Treatments in this trial (4522lUOO65) included RSV 10, 20, 40, or 80 mg; AlV 10, 
20, 40, or 80 mg; SIM 10, 20, 40, or 60 mg; and PRA 10. 20, or 40 mg. Prospectively 
planned analyses for each lipid included log-dose-response curve analyses and 25 
selected pair-wise comparisons of RSV doses with corresponding or higher doses of 
comparators (with a statistical significance level adjustment to 0.002 to account for multi- 
ple compahsons). 
Results: The table shows dose-to-dose comparisons. Baselrne LDL-C means were 187 
to 194 mg/dL. The curves analysis showed that RSV produced a mean 8.2% greater 
LDL-C reduction (pc.001) than AN across the dose ranges. Greater differences in LDL- 
C reduction were observed between RSV and PRA or SIM. 
